Increased Awareness of Myopia Treatment drives Europe Myopia Treatment Market
The heightened awareness of myopia treatment options drives the substantial growth of the myopia treatment market. A recent market analysis revealed that the increasing awareness of myopia management strategies, particularly among parents and eyecare professionals, has led to a significant upsurge in implementing myopia control measures. The leader in global eye care is teaming up with three of the best optometry schools in the country to provide extended myopia therapy to a pilot group starting in 2024. As awareness campaigns, educational initiatives, and extensive research studies continue to shed light on the potential consequences of unmanaged myopia, there has been a notable shift toward proactive myopia management approaches.This trend has furthered the adoption of myopia treatment technologies, such as orthokeratology and pharmaceutical interventions, resulting in a remarkable increase in the market size, which has grown by over 25% in the last two years. The collective efforts to raise awareness about myopia as a public health concern and to promote the viability of myopia management solutions are propelling market growth and fostering a culture of proactive vision care. This momentum is likely to continue driving advancements in myopia treatment, emphasizing the pivotal role of awareness in shaping the landscape of myopia management and treatment strategies.
Europe Myopia Treatment Market Overview
The Europe myopia treatment market includes the consolidated markets for Germany, France, the UK, Spain, Italy, and the Rest of Europe. Europe occupies a significant position in the global myopia treatment market and is estimated to register a robust growth rate during the forecast period. The market growth in the region is expected due to the increasing geriatric population, rising emphasis on preventive care in Europe, and rising number of product introductions in the region. Germany's extensively increasing geriatric population represents a lucrative opportunity for increased adoption of eye health supplements in the country.As per the "World Population Ageing 2017," in 2017, ~28% of the total population of Germany was aged 60 or more, and it is estimated to rise to nearly 37.6% by the year 2050. It also mentioned that life expectancy is projected to be 83 years for women and 78 years for men. Such higher life expectancy will likely impact eye health, eventually driving the Germany myopia treatment market during the forecast period.
Europe Myopia Treatment Market Segmentation
The Europe myopia treatment market is categorized into type, treatment, age group, end user, and country.- Based on type, the Europe myopia treatment market is segmented into high myopia, degenerative myopia, and progressive myopia. The high myopia segment held the largest Europe myopia treatment market share in 2022.
- In terms of treatment, the Europe myopia treatment market is segmented into low-dose atropine eye drops, contact lenses, ortho-k, and refractive surgery. The low-dose atropine eye drops segment held the largest Europe myopia treatment market share in 2022. Furthermore, the refractive surgery segment is subcategorized into LASIK and PRK.
- By age group, the Europe myopia treatment market is bifurcated into adult myopia and childhood myopia. The adult myopia segment held a larger Europe myopia treatment market share in 2022.
- Based on end user, the Europe myopia treatment market is categorized into hospitals and clinics, specialty clinics, and refractive surgery centers. The hospitals and clinics segment held the largest Europe myopia treatment market share in 2022.
- Based on country, the Europe myopia treatment market is categorized into Germany, the UK, Italy, France, Spain, and the Rest of Europe. Germany dominated the Europe myopia treatment market share in 2022.
Table of Contents
Companies Mentioned
- Alcon AG
- Bausch Health Companies Inc
- Carl Zeiss AG
- CooperVision Inc
- Eyes Vision SL
- Haag-Streit AG
- Johnson & Johnson Vision Care Inc
- Nidek Co Ltd
- Ziemer Ophthalmic Systems AG